Biology Reference
In-Depth Information
References
1. Dehay B, Bezard E (2011) New animal mod-
els of Parkinson's disease. Mov Disord
26(7):1198-1205
2. Tuszynski MH (2007) Nerve growth factor
gene therapy in Alzheimer disease. Alzheimer
Dis Assoc Disord 21(2):179-189
3. Porras G et al (2012) PSD-95 expression con-
trols L-DOPA dyskinesia through dopamine
D1 receptor traffi cking. J Clin Invest 122(11):
3977-3989
4. Ahmed MR et al (2010) Lentiviral overexpres-
sion of GRK6 alleviates L-dopa-induced dyski-
nesia in experimental Parkinson's disease. Sci
Transl Med 2(28):28ra28
5. Meissner WG et al (2011) Priorities in
Parkinson's disease research. Nat Rev Drug
Discov 10(5):377-393
6. Tuszynski MH et al (2005) A phase 1 clinical
trial of nerve growth factor gene therapy for
Alzheimer disease. Nat Med 11(5):551-555
7. Marks WJ Jr et al (2010) Gene delivery of
AAV2-neurturin for Parkinson's disease: a
double-blind, randomised, controlled trial.
Lancet Neurol 9(12):1164-1172
8. Lundberg C et al (2008) Applications of lenti-
viral vectors for biology and gene therapy of
neurological disorders. Curr Gene Ther
8(6):461-473
9. Kordower JH et al (1999) Lentiviral gene
transfer to the nonhuman primate brain. Exp
Neurol 160(1):1-16
10. Kordower JH (2003) In vivo gene delivery of
glial cell line—derived neurotrophic factor for
Parkinson's disease. Ann Neurol 53(Suppl
3):S120-S132, discussion S132-4
11. Gash DM, Gerhardt GA, Hoffer BJ (1998)
Effects of glial cell line-derived neurotrophic
factor on the nigrostriatal dopamine system in
rodents and nonhuman primates. Adv
Pharmacol 42:911-915
12. Kordower JH et al (2000) Neurodegeneration
prevented by lentiviral vector delivery of
GDNF in primate models of Parkinson's dis-
ease. Science 290(5492):767-773
13. Palfi S et al (2002) Lentivirally delivered glial
cell line-derived neurotrophic factor increases
the number of striatal dopaminergic neurons
in primate models of nigrostriatal degenera-
tion. J Neurosci 22(12):4942-4954
14. Jarraya B et al (2009) Dopamine gene therapy
for Parkinson's disease in a nonhuman primate
without associated dyskinesia. Sci Transl Med
1(2):2ra4
15. Bezard E, Brotchie JM, Gross CE (2001)
Pathophysiology of levodopa-induced dyski-
nesia: potential for new therapies. Nat Rev
Neurosci 2(8):577-588
16. Fahn S (2006) Levodopa in the treatment of
Parkinson's disease. J Neural Transm Suppl
(71):1-15
17. Guigoni C, Doudnikoff E, Li Q, Bloch B,
Bezard E (2007) Altered D(1) dopamine
receptor traffi cking in parkinsonian and dyski-
netic non-human primates. Neurobiol Dis
26(2):452-463
18. Bezard E et al (2005) L-DOPA reverses the
MPTP-induced elevation of the arrestin2 and
GRK6 expression and enhanced ERK activa-
tion in monkey brain. Neurobiol Dis 18(2):
323-335
19. Fasano S et al (2010) Inhibition of Ras-
guanine nucleotide-releasing factor 1 (Ras-
GRF1) signaling in the striatum reverts motor
symptoms associated with L-dopa-induced
dyskinesia. Proc Natl Acad Sci USA
107(50):21824-21829
20. Pearce RK, Jackson M, Smith L, Jenner P,
Marsden CD (1995) Chronic L-DOPA admin-
istration induces dyskinesias in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine-treated
common marmoset (Callithrix Jacchus). Mov
Disord 10(6):731-740
21. Gold SJ et al (2007) RGS9-2 negatively mod-
ulates L-3,4-dihydroxyphenylalanine-induced
dyskinesia in experimental Parkinson's disease.
J Neurosci 27(52):14338-14348
22. Nash JE, Johnston TH, Collingridge GL,
Garner CC, Brotchie JM (2005) Subcellular
redistribution of the synapse-associated pro-
teins PSD-95 and SAP97 in animal models of
Parkinson's disease and L-DOPA-induced dys-
kinesia. FASEB J 19(6):583-585
23. Palfi S et al (2007) Expression of mutated
huntingtin fragment in the putamen is
suffi cient to produce abnormal movement in
non-human primates. Mol Ther 15(8):
1444-1451
24. Kwon I, Schaffer DV (2008) Designer gene
delivery vectors: molecular engineering and
evolution of adeno-associated viral vectors for
enhanced gene transfer. Pharm Res 25(3):
489-499
25. Zhang H, Xie J, Xie Q, Wilson JM, Gao G
(2009) Adenovirus-adeno-associated virus
hybrid for large-scale recombinant adeno-
associated virus production. Hum Gene Ther
20(9):922-929
26. Gao G, Vandenberghe LH, Wilson JM (2005)
New recombinant serotypes of AAV vectors.
Curr Gene Ther 5(3):285-297
27. Gao GP et al (2002) Novel adeno-associated
viruses from rhesus monkeys as vectors for
human gene therapy. Proc Natl Acad Sci USA
99(18):11854-11859
Search WWH ::
Custom Search